Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy

References

• Carr C, Ng J, Wigmore T. The side effects of chemotherapeutic agents. Curr Anaesth Crit Care 2008;19:70–9
   Google Scholar
• Allen TM, Charrois GJR, Sapra P. Recent advances in passively and actively targeted liposomal drug delivery systems for the treatment of cancer. Abstracts of Papers of the American Chemical Society. 2003;226:U458–U
   Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818–22
   PubMed Web of Science ®Google Scholar
• Banciu M, Metselaar JM, Schiffelers RM, Storm G. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol 2008;111:101–10
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415–27
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Invest Drugs (Lond, England: 2000) 2006;7:522–8
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001;60:155–61
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2000;21:93–102
   Web of Science ®Google Scholar
• Tozer G, Kanthou C, Lewis G, et al. Tumour vascular disrupting agents: combating treatment resistance. Brit J Radiol 2008;81:12–20
   Google Scholar
• Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229–33
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Shreeves G, Nathan PD, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010;102:1355–60
   PubMed Web of Science ®Google Scholar
• Zweifel M, Jayson G, Reed N, et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results. J Clin Oncol 2009;27:15S. Abstr no: 5502
   Google Scholar
• Wildiers H, Ahmed B, Guetens G, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer. 2004;40:284–90
   PubMed Web of Science ®Google Scholar
• Wang HJ, Sun XH, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009;44:44–53
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009;44:44–53
   PubMed Web of Science ®Google Scholar
• Feng Y, Xie Y, Wang H, et al. A modified rabbit model of reperfused myocardial infarction for cardiac MR imaging research. Int J Cardiovasc Imaging 2009;25:289–98
   PubMed Web of Science ®Google Scholar
• Li X, Coles BJ, Ramsey MH, Thornton I. Sequential extraction of soils for multielement analysis by ICP-AES. Chem Geol 1995;124:109–23
   Web of Science ®Google Scholar
• Zhao F, McGrath S, Crosland A. Comparison of three wet digestion methods for the determination of plant sulphur by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Commun Soil Sci Plant Anal 1994;25:407–18
   Web of Science ®Google Scholar
• Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Therapy Rev 2005;1:1–9
   Google Scholar
• Tozer G, Kanthou C. Tumor vascular disrupting agents. In: Domenico Ribotti, ed. Recent advances in angiogenesis and antiangiogenesis. Sharjah: Bentham Science Publishers; 2009:101–11
   Google Scholar
• Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457–64
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnology, Methods Mol Biol 2010;624:25–37
   PubMedGoogle Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812–18
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Popovic Z, Liu WH, Chauhan VP, et al. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem, Int Ed 2010;49:8649–52
   PubMed Web of Science ®Google Scholar
• Weinmann H-J, Brasch RC, Press W-R, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 1984;142:619–24
   PubMed Web of Science ®Google Scholar
• Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925–32
   PubMed Web of Science ®Google Scholar
• Dreher MR, Liu WG, Michelich CR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335–44
   PubMed Web of Science ®Google Scholar